Tharimmune Employees

As of December 31, 2023, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees increased by 1 or 50.00% compared to the previous year.

Employees

Change (1Y)

Growth (1Y)

50.00%

Revenue / Employee

n/a

Profits / Employee

-$2,958,353

Market Cap

3.34M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	3	1	50.00%
Dec 31, 2022	2	0	-
Dec 31, 2021	2	-	-

Related Stocks

Company Name	Employees
Venus Concept	304
Regional Health Properties	114
Molecular Templates	62
iSpecimen	53
Matinas BioPharma Holdings	32
Scinai Immunotherapeutics	31
ReShape Lifesciences	29
TNF Pharmaceuticals	6

Employee Rankings

THAR News

1 day ago - Tharimmune Announces Upcoming Conference Presentations - Accesswire
6 days ago - Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - Accesswire
8 days ago - Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - Accesswire
5 weeks ago - Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company - Accesswire
7 weeks ago - Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - Accesswire
3 months ago - Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board - Accesswire
3 months ago - Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor - Accesswire
5 months ago - Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - Accesswire

More News